Literature DB >> 26998740

Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma.

Benjamin M Ellingson1,2,3,4,5,6, Huytram N Nguyen3,7, Albert Lai3,7, Ruben E Nechifor1,2, Okkar Zaw1,2, Whitney B Pope2, William H Yong8, Phioanh L Nghiemphu3,7, Linda M Liau3,9, Timothy F Cloughesy3,7.   

Abstract

BACKGROUND: Little is known about the natural growth characteristics of untreated glioblastoma before surgical or therapeutic intervention, because patients are rapidly treated after preliminary radiographic diagnosis. Understanding the growth characteristics of uninhibited human glioblastoma may be useful for characterizing changes in response to therapy. Thus, the objective of the current study was to explore tumor growth dynamics in a cohort of patients with untreated glioblastoma before surgical or therapeutic intervention.
METHODS: Ninety-five patients with glioblastoma who had measurable enhancing disease on >2 magnetic resonance imaging scans before surgery were identified. Tumor growth rates were quantified in 4 different ways (the percentage change per day, the absolute rate of change per day, the estimated volumetric doubling time, and the radial expansion rate) using 3 different approaches (bidirectional product, enhancing disease, and total lesion volume).
RESULTS: The median volumetric doubling time was 21.1 days, the percentage change in tumor volume was 2.1% per day, and the rate of change in total lesion volume was 0.18 cc per day. The length of follow-up between magnetic resonance imaging examinations should be >28 days to detect progressive disease with high specificity. Small initial tumor sizes (<3 cm in greatest dimension) are biased toward a large percentage change at follow-up.
CONCLUSIONS: Presurgical, treatment-naive glioblastoma growth dynamics can be estimated in a variety of ways with similar results. The percentage changes in tumor size and volume depend on baseline tumor size and the time interval between scans. Cancer 2016;122:1718-27.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  T1 subtraction; glioblastoma; growth rates; volumetry

Mesh:

Substances:

Year:  2016        PMID: 26998740     DOI: 10.1002/cncr.29957

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

1.  Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma.

Authors:  Ararat Chakhoyan; Davis C Woodworth; Robert J Harris; Albert Lai; Phioanh L Nghiemphu; Linda M Liau; Whitney B Pope; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2018-05-31       Impact factor: 4.130

2.  Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy.

Authors:  Chan Woo Wee; Eunji Kim; Tae Min Kim; Chul-Kee Park; Jin Wook Kim; Seung Hong Choi; Roh-Eul Yoo; Soon-Tae Lee; Il Han Kim
Journal:  J Neurooncol       Date:  2017-05-25       Impact factor: 4.130

3.  Peptide P11 suppresses the growth of human thyroid carcinoma by inhibiting the PI3K/AKT/mTOR signaling pathway.

Authors:  Dongdong Wu; Wenke Tian; Jianmei Li; Qianqian Zhang; Honggang Wang; Lei Zhang; Zhongwen Xie; Ailing Ji; Yanzhang Li
Journal:  Mol Biol Rep       Date:  2019-04-26       Impact factor: 2.316

4.  Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.

Authors:  Jerrold L Boxerman; Zheng Zhang; Yair Safriel; Jeffrey M Rogg; Ronald L Wolf; Suyash Mohan; Helga Marques; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 12.300

5.  Improved Survival with Decreased Wait Time to Surgery in Glioblastoma Patients Presenting with Seizure.

Authors:  Patrick M Flanigan; Arman Jahangiri; Ruby Kuang; Albert Truong; Sarah Choi; Alvin Chou; Jonathan W Rick; Susan M Chang; Annette M Molinaro; Michael W McDermott; Mitchel S Berger; Manish K Aghi
Journal:  Neurosurgery       Date:  2017-11-01       Impact factor: 4.654

Review 6.  Neuroimaging of traumatic brain injury in military personnel: An overview.

Authors:  Avnish Bhattrai; Andrei Irimia; John Darrell Van Horn
Journal:  J Clin Neurosci       Date:  2019-07-19       Impact factor: 1.961

7.  Clinical, histopathological, and molecular features of IDH-wildtype indolent diffuse glioma: comparison with typical glioblastoma.

Authors:  Hayato Suzuki; Takahiro Ono; Souichi Koyota; Masataka Takahashi; Tamotsu Sugai; Hiroshi Nanjo; Hiroaki Shimizu
Journal:  J Neurooncol       Date:  2022-07-02       Impact factor: 4.506

8.  Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements.

Authors:  Felice D'Arco; Patricia O'Hare; Fatima Dashti; Alvaro Lassaletta; Thalia Loka; Uri Tabori; Giacomo Talenti; Stefanie Thust; Giancarlo Messalli; Patrick Hales; Eric Bouffet; Suzanne Laughlin
Journal:  Neuroradiology       Date:  2018-01-30       Impact factor: 2.804

9.  Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.

Authors:  Benjamin M Ellingson; Lauren E Abrey; Josep Garcia; Olivier Chinot; Wolfgang Wick; Frank Saran; Ryo Nishikawa; Roger Henriksson; Warren P Mason; Robert J Harris; Kevin Leu; Davis C Woodworth; Arnav Mehta; Catalina Raymond; Ararat Chakhoyan; Whitney B Pope; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

10.  Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study.

Authors:  Domenique M J Müller; Merijn E De Swart; Hilko Ardon; Frederik Barkhof; Lorenzo Bello; Mitchel S Berger; Wim Bouwknegt; Wimar A Van den Brink; Marco Conti Nibali; Roelant S Eijgelaar; Julia Furtner; Seunggu J Han; Shawn Hervey-Jumper; Albert J S Idema; Barbara Kiesel; Alfred Kloet; Emmanuel Mandonnet; Pierre A J T Robe; Marco Rossi; Tommaso Sciortino; W Peter Vandertop; Martin Visser; Michiel Wagemakers; Georg Widhalm; Marnix G Witte; Philip C De Witt Hamer
Journal:  Neurooncol Adv       Date:  2021-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.